Puma Biotechnology | PBYI - Actif À Court Terme





Actif À Court Terme Changement Date
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Amgen USD 31.48B 2.42B 2026-03
Biogen USD 9.19B 216.3M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Daiichi Sankyo JPY 2.1T 218.5B 2025-12
Esperion Therapeutics USD 459.46M 3.11M 2026-03
Exelixis USD 1.21B 234.65M 2026-03
Gilead Sciences USD 18.64B 1.25B 2026-03
Glaxosmithkline GBP 23.59B 390.44M 2025-12
Incyte USD 5.48B 460.36M 2026-03
MacroGenics USD 182.52M 37.42M 2026-03
Moderna USD 5.77B 774M 2026-03
Novartis USD 26.61B 3.85B 2026-03
Pfizer USD 42.82B 76M 2026-03
PTC Therapeutics USD 2.25B 19.94M 2026-03
Puma Biotechnology USD 143.58M 7M 2025-09
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Roche Holding CHF 38.73B 3.03B 2025-12
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
Takeda JPY 3.09T 25.94B 2026-03
TG Therapeutics USD 1.09B 456.2M 2026-03
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03